Editorial: The changing landscape of cystic fibrosis: new therapies, challenges and a global pandemic
No abstract available
Although many physicians believed that cystic fibrosis patients would be hard-hit by COVID-19, that has not happened. How has this group managed the pandemic so well?Southern Medical Journal
Polarean Imaging, a company based in North Carolina, is pursuing regulatory approval for clinical use of its hyperpolarized gas MRI. The technology is intended to assist in diagnosing respiratory conditions, something that would be particularly usefu...
Severe acute respiratory syndrome – coronavirus-2 (SARS-CoV-2), has caused a pandemic of unknown example to date . The World Health Organization described the disease caused by SARS-CoV-2 coronavirus disease 2019 (COVID-19) . The COVID-19 pandemic impacted in health care systems worldwide, its long-term consequences are stil l to be seen. To date, predictors for the development of severe COVID-19 have not been well established; however, patients with chronic lung diseases among other risk factors are more likely to suffer .
Cystic Fibrosis (CF) is the most common life shortening genetic disorder with a worldwide prevalence of about 1 in 4000 births. CF is a multi-organ disease, affecting lungs and digestive system. The daily intensive treatment has multiple components and is considered a heavy burden on patients and their families. Although life expectancy has increased over the past decade and is expected to improve further with promising CFTR modulators, no cure is presently available. Thus far, lung transplantation (LTX) is the only option to overcome respiratory insufficiency, but LTX involves further chronic comorbidities requiring intensive treatment.
By now, we all know the drill: Maintain physical distance. Wear a mask. Wash your hands. Avoid people who are sick and stay away from others if you are sick. While these measures may seem simple enough, they are not easy to keep up month after month. Yet they are likely to be with us for a while. But what about those who cannot comply? Certain conditions can make the standard measures to stay safe during the pandemic seem impossible. At the same time, some of those likely to have the most trouble following the guidelines — such as older people with dementia — are at higher risk for illness and death if they do ...
CFHealthHub is a digital platform to help adults with cystic fibrosis manage their condition and monitor their medicine use. Evidence from a randomised feasibility study and two economic studies is discussed; the results of a UK RCT (n=607) are due for publication later this year
AireHealth, a medtech company based in Orlando, Florida, currently offers a portable nebulizer and companion app for respiratory patients aged two and over. The small nebulizer can be charged using a micro USB charger and then placed in a bag or pock...
As our attention has been distracted to address issues related to the novel coronavirus (COVID-19) and we are hoping to be relieved of its disruption to our lives, we must remember that when it is all over, our patients and their families are still dealing with the consequences of cystic fibrosis (CF). All that we had been working on prior to the pandemic remains as important as before. Through all of this the Journal of Cystic Fibrosis (JCF) has continued to receive submitted manuscripts. We appreciate the dedication of our Associate Editors and the reviewers who have continued to respond to the work involved in the peer review process.
A cluster of cases of pneumonia of unknown origin presented in Wuhan, China in early December 2019; the cause was subsequently found to be a novel coronavirus, now named SARS-Cov-2 . This new virus is highly transmissible and has resulted in a pandemic with over 2 million confirmed infections and more than 145,000 deaths in humans in 185 countries .
While other companies are tempering or staying mum on annual sales forecasts amid the COVID-19 pandemic, booming sales of its new cystic fibrosis drug have led Vertex to increase its expectations.